On 23 June 2025, TransThera Sciences (Nanjing), Inc. (2617.HK, TransThera) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 201 million. CBI is honored to participate in the due diligence work for this IPO Project.

TransThera is a China-based biopharmaceutical company principally focusing on discovering and developing innovative small molecule therapies for oncology, inflammatory and cardiometabolic diseases. The company has various oncology pipelines with products that are capable of being efficacious in a broad range of cancer types (including prostate cancer, HCC, breast cancer, and BTC).

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, and shareholders by providing information including litigation, bankruptcy, winding-up and media records in China, Hong Kong and the United States.